Polyamine reduced diet and low dose metronomic cyclophosphamide in hormone refractory prostate cancer (HRPC) patients

被引：0
|
作者：
Cipolla, B. G. [1 ,2 ]
Havouis, R. [1 ]
Moulinoux, J. P. [1 ]
机构：
[1] Univ Rennes 1, CNRS, URA 1529, F-35014 Rennes, France
[2] CHP St Gregoire, Rennes, France
来源：
AMINO ACIDS | 2009年 / 37卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [21] Natural history of patients with hormone refractory prostate cancer (HRPC): are they living longer?
    Patel, P.
    Houston, V.
    Hayne, D.
    James, N. D.
    BJU INTERNATIONAL, 2010, 105 : 4 - 4
  • [22] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Bellmunt, Joaquim
    Carles, Joan
    Albanell, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02): : 82 - 85
  • [23] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Joaquim Bellmunt
    Joan Carles
    Joan Albanell
    Clinical and Translational Oncology, 2009, 11 : 82 - 85
  • [24] Clinical outcome of patients (pts) with taxane-resistant (TR) hormone-refractory prostate cancer (HRPC) treated with second-line cyclophosphamide (CP) -based metronomic chemotherapy
    Nelius, T.
    Klatte, T.
    de Riese, W.
    Filleur, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Zoledronic acid and Taxotere (ZANTE) metronomic and sequential administration in patients with hormone refractory prostate cancer (HRPC) - final results of phase I study
    Caraglia, M.
    Morabito, A.
    Marra, M.
    Bochicchio, A. M.
    Piccirillo, M. C.
    Franco, R.
    Perrone, F.
    Budillon, A.
    Iaffaioli, R. V.
    Facchini, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 134 - 134
  • [26] Gefitinib (IressaTM) combined with endocrine manipulation in patients with hormone refractory prostate cancer (HRPC).
    de Braud, FG
    Curigliano, G
    De Pas, T
    Noberasco, C
    Renne, G
    Zorzino, L
    Scardino, E
    Del Monaco, D
    De Cobelli, O
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9022S - 9022S
  • [27] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients
    Humphreys, M. R.
    Ma, C.
    Sridhar, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
    Fontana, Andrea
    Galli, Luca
    Fioravanti, Anna
    Orlandi, Paola
    Galli, Costanza
    Landi, Lorenza
    Bursi, Simona
    Allegrini, Giacomo
    Fontana, Eloise
    Di Marsico, Roberta
    Antonuzzo, Andrea
    D'Arcangelo, Manolo
    Danesi, Romano
    Del Tacca, Mario
    Falcone, Alfredo
    Bocci, Guido
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4954 - 4962
  • [29] NAVELBIN AS A SECOND LINE TREATMENT FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Jana, J. K.
    Rovny, A. R.
    Divisova, K. D.
    Filipensky, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 658 - 659
  • [30] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results
    Fontana, A.
    Bocci, G.
    Galli, L.
    Fontana, E.
    Galli, C.
    Landi, L.
    Fioravanti, A.
    Di Marsico, R.
    Del Tacca, M.
    Facone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 288 - 288
12345